Brand Intelligence Graph
Company Overview
About Agomab Therapeutics
Agomab Therapeutics went public on Nasdaq in February 2026, raising approximately $200 million at an ~$780 million valuation (ticker: AGMB), becoming one of the first European biotechs to list in the US in 2026. Agomab is developing ontunisertib — the only clinical-stage gut-restricted ALK5/TGFβR1 inhibitor for fibrostenosing Crohn's disease, a severe complication where intestinal fibrosis causes strictures requiring repeated surgery. The company also has AGMB-447 in Phase 1 for idiopathic pulmonary fibrosis (IPF), using lung-restricted delivery of the same mechanism.
Business Model & Competitive Advantage
Fibrostenosing Crohn's disease affects approximately 30% of Crohn's patients and has zero approved treatments specifically for the fibrotic complication — standard Crohn's therapies address inflammation but not the fibrotic strictures that cause bowel obstruction. Ontunisertib's gut-restricted delivery (not absorbed systemically) targets the fibrotic process directly in intestinal tissue while avoiding the systemic side effects that broad TGFβ inhibition causes.
Competitive Landscape 2025–2026
The dual-indication strategy using lung-restricted versus gut-restricted delivery of the same ALK5 inhibitory mechanism provides clinical efficiency: positive proof-of-concept data in one indication validates the mechanism for the other, and the development infrastructure for both programs is largely shared. Agomab's Nasdaq listing provides capital market access for both development programs simultaneously.
Key Differentiators
Emerging Innovator
Agomab Therapeutics is an emerging player bringing innovative solutions to the BioTech market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Regeneron
Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized m
Vivtex
Vivtex is an MIT Langer Laboratory spinout that has developed a drug delivery platform enabling oral administration of biologics — proteins, peptides, and other large molecules — that have historicall
Prime Medicine
Prime Medicine is a publicly-traded (Nasdaq: PRME) clinical-stage biotech developing Prime Editing — the most versatile and precise gene editing technology currently entering clinical trials, capable
Compare Agomab Therapeutics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Agomab Therapeutics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Agomab Therapeutics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Agomab Therapeutics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →